5-alpha-reductase inhibitors are associated with increased sexual adverse events in androgenetic alopecia patients
Hair loss medications may cause some side effects for men
This systematic review of 41 studies evaluates the impact of finasteride and dutasteride on sexual dysfunction in patients with hair loss. T…
Men using finasteride or dutasteride for hair loss may experience sexual side effects, though most cases are mild and reversible when the dr…
Sacituzumab Tirumotecan Combined With Pembrolizumab Improves Outcomes in PD-L1 Positive NSCLC
Trial shows combination therapy improves survival in lung cancer
A Phase 3 trial shows that adding sacituzumab tirumotecan to pembrolizumab significantly extends progression-free survival in advanced NSCLC…
A new drug combination significantly extends the time patients with advanced lung cancer live without their disease progressing.
Perampanel provides seizure freedom for 42% of patients with brain tumor-related epilepsy
Perampanel Shows Promise for Seizures Linked to Brain Tumors
This meta-analysis of real-world clinical data evaluates perampanel for managing seizures in patients with brain tumors. The analysis found …
A review of real-world data suggests that the medication perampanel can help many patients manage seizures caused by brain tumors.
Meta-analysis Evaluating Occupational Hexavalent Chromium Exposure and Specific Malignancy Risks
Occupational Chromium Exposure Linked to Bladder Cancer Mortality
A meta-analysis of 29 publications examined how occupational hexavalent chromium exposure impacts various cancer types in human populations.
A review of 29 publications found that while most cancers showed no link, bladder cancer mortality was associated with hexavalent chromium e…
CRT plus EGFR-TKI improves overall survival while EGFR-TKI plus RT ranks first for progression-free survival
Trial Shows Specific Drug Combinations Improve Lung Cancer Survival
This systematic review and network meta-analysis of 1,529 patients with unresectable stage III EGFR-mutated non-small cell lung cancer compa…
New research identifies specific combinations of targeted therapies that may improve survival and manage side effects for certain types of l…
Extended resection and intensity-modulated radiotherapy managed a rare primary orbit epithelioid sarcoma
Treatment approach for a rare orbit tumor in a young man
This case report describes the diagnosis and management of a 25-year-old male with primary epithelioid sarcoma of the left orbit. The patien…
A 25-year-old man with a rare eye tumor showed no signs of cancer spread after surgery and targeted radiation therapy.
Walking training improves VO2 peak and reduces fatigue in adult cancer patients
Walking Training May Improve Fitness and Reduce Fatigue in Cancer Patients
This meta-analysis of 649 adult cancer patients found that walking training significantly improved VO2 peak (SMD = 0.56) and reduced fatigue…
Walking training may improve oxygen uptake and reduce fatigue for people living with cancer, according to a review of several clinical studi…
Regenerative medicine strategies show feasibility for dentin-pulp complex regeneration in dental pulp disease
New regenerative methods show promise for treating dental pulp disease
This mini-review examines regenerative medicine strategies, including stem cell biology and bioactive scaffolds, for treating dental pulp di…
New research explores how stem cells and advanced materials could help regrow damaged tissue inside teeth to improve long term outcomes.
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
FDA Approves Ibrance (palbociclib) for PIK3CA-Mutated Breast Cancer
FDA approves Ibrance combination for certain advanced breast cancer patients.
The FDA approved Ibrance (palbociclib) in combination with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, …
The FDA approved Ibrance (palbociclib) with inavolisib and fulvestrant for adults with a specific type of advanced breast cancer that has a …
FDA Approves Ibrance (palbociclib) for HR-Positive, HER2-Negative Advanced Breast Cancer
FDA approves new drug Ibrance for certain advanced breast cancers.
The FDA approved Ibrance (palbociclib) for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase …
The FDA approved Ibrance (palbociclib) for adults with HR-positive, HER2-negative advanced or metastatic breast cancer. It is used with othe…
FDA Approves Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- Breast Cancer
FDA approves Trodelvy for a common type of advanced breast cancer.
The FDA approved Trodelvy for unresectable locally advanced or metastatic HR+/HER2- breast cancer after endocrine-based therapy and at least…
The FDA approved Trodelvy for adults with advanced HR-positive, HER2-negative breast cancer who have tried hormone therapy and at least two …